Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Wades Into the Opioid Debate

This article was originally published in RPM Report

Executive Summary

Reducing prescription drug abuse is a high priority item for several key legislators and for the Obama Administration. Proposed new rules for Medicare drug plan sponsors might help—but they also underscore the growing tension among the many different stakeholders in the pharmaceutical supply chain.


Related Content

“Messing With Success”: CMS’ Case For Changing Part D – And How Data Sharing May Help
Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start
Part D 2014 Draft Call Letter Addresses Automatic Rx Refills, Drug Safety Issues
Part D: “Very Successful” Does Not Mean “Perfect”
CMS and Opioids: The Role for Non-Drug Reimbursements
Regulatory Alchemy: The Transformative Power of the Opioid REMS
Controlling Opioids: REMS Meets Congressional Resistance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts